{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-24-000114","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.108764+00:00","generated_at":"2026-05-30T11:40:30.183323+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas achieves in vivo preclinical proof of concept for sickle cell; seeks partner for reni-cel","bullets":["Achieved 29% HSPC editing and 20% HbF-expressing red blood cells in humanized mice after single dose using proprietary tLNP.","Initiated process to partner or out-license reni-cel; engaged Moelis & Company to lead global process.","Q3 2024 cash, equivalents, and marketable securities ~$265M; ~$320M after $57M upfront from DRI Healthcare.","On track to present substantive RUBY trial SCD data at ASH December 2024; EdiTHAL data by year-end 2024.","Company will not host Q3 2024 earnings call; strategic update webinar held October 22, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-24-000114","json":"https://secwatch.observer/filing/0001650664-24-000114.json","markdown":"https://secwatch.observer/filing/0001650664-24-000114.md","text":"https://secwatch.observer/filing/0001650664-24-000114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000114/0001650664-24-000114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066424000114/edit-20241022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:40:30.183323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}